No Data
Bausch + Lomb (NYSE:BLCO) Has A Somewhat Strained Balance Sheet
Why Is Clearside Biomedical Stock Gaining Today?
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $23
Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 59.9% and
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23
Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 60.1
Bausch + Lomb INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States